GRAIL is a healthcare company focused on alleviating the global burden of cancer by detecting it early, when it may be more treatable and potentially curable. The company leverages next-generation sequencing, population-scale clinical studies, and advanced machine learning to develop innovative cancer detection technologies.
Its flagship product, the Galleri® test, is a multi-cancer early detection (MCED) blood test designed to screen for multiple deadly cancers before symptoms appear, including those without standard screening methods. GRAIL aims to transform cancer care by identifying cancer signals and predicting their origin in the body.
The company is backed by rigorous clinical research, with over 385,000 participants across its clinical programs and more than 300 scientific publications. GRAIL operates CAP-accredited, CLIA-certified laboratories with significant capacity to support its mission at scale.
